MYocardial viability

Current Problems in Cardiology

Volumn 21, Issue 3, 1996, Pages 147-221

  Hendel, Robert C ^a   Chaudhry, Farooq A ^a   Bonow, Robert O ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM;

CELL SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYTOLOGY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HUMAN; PATHOPHYSIOLOGY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CELL SURVIVAL; ECHOCARDIOGRAPHY; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; TECHNETIUM TC 99M SESTAMIBI; THALLIUM RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0030099487     PISSN: 01462806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0146-2806(96)80009-0     Document Type: Article

References (260)

1. Hammermeister K, DeRouen T, Dodge H. Variables predictive of survival in patients with coronary disease: selection by univariate and multivariate analysis from the clinical, electrocardiographic, exercise, arteriographie, and quantitative angiographie evaluations. Circulation 1979:59:421-30.
2. Bruschke A, Proud fit W, Sones F. Progress study of 590 consecutive nonsurgical cases of coronary artery diseased followed 5-9 years. II. Ventriculographic and other correlations. Circulation 1973;47:1154-63.
3. Harris P, Harrel F. Lee K. Behar V. Rosati R. Survival in medically treated coronary artery disease. Circulation 1979:60:1259-69.
4. Emond M, Mock M, Davis K. et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASK) Registry. Circulation 1994:90:2645-57.
5. Mock M, Ringqvist I, Fisher L, et al. Survival of medically treated patients in the Coronary Artery Surgery Study (CASS) registry. Circulation 1982:66:562-8.
6. Bolli R. Myocardial "stunning" in man. Circulation 1992:86:1671-91.
7. Braunwald K. Kloner R. The stunned myocardium: prolonged, post ischemic ventricular dysfunction. Circulation 1982:66:1146-9.
8. Anderson J, Marshall H, Bray B, et al. A randomized trial of intracoronary streptokinasii in the treatment of acute myocardial infarction. N Engl J Mod 1983:300:1312-8.
9. Reduto L, Freund C. Baeta f, Smalling R, Lewis B, Could K. Coronary artery reperfusion in acute myocardial infarction: beneficial effects of intracoronary slreptokinase on left ventricular salvage and performance. Am Heart J 1981:102:1108-77.
10. Stack R, Phillips HI, Crierson D, et al. Functional improvement of jeopardized myocardium following intracoronary streptokinase infusion in acute myocardial infarction. J Clin Invest 1983:72:84-95.
11. Shoehan F. Doerr R. Schmidt W. et al. Early recovery of left ventricular function after thrombolylic therapy for acute myocardial infarction: an important determinant of survival, J Am Coli Cardiol 1988:12:289-300.
12. Topol E. Weiss |. Brinker L. Brin K. Gottlieb S, Beckcr L. Regional wall motion improvement after coronary thrombolysis with recombinant tissue plasminogen activator: importance of coronary angioplasty. J Am Coll Cardiol 1985:6:426-33.
13. Helfant R, Pine R. Meister S, Feldman M. Trout R, Banka U. Nitroglycerine to unmask reversible asynergy: correlation with post coronary bypass ventriculography. Circulation 1974:50:108-13.
14. Rahimtoola S. The hibernating myocardium. Am Heart J 1989:117:211-20.
15. Rahimtoola S. Coronary bypass surgery for chronic angina-1981: a perspective. Circulation 1982:65:225-41.
16. Braunwald E, Rutherford J. Reversible ischemie left ventricular dysfunction: evidence for "hibernating" myocardium. J Am Coll Cardiol 1986:8:1467-70.
17. Elefleriades J. To lis GJ, Levi FJ. Mills L. Zaret B. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol 1993:22:1411-7.
18. Dilsizian V, Bonow R, Cannon R, et al. The effect of coronary artery bypass grafting on left ventricular systolic function at rest: evidence for preoperative subclinical myocardial ischemia. Am J Cardiol 1988;61:1248-54.
19. Ross JJ. Myocardial perfusion-contraction matching: implications for coronary artery disease and hibernation. Circulation 1991;83:1076-83.
20. Iskandrian A, Heo J, Stanberry C. When is myocardial viability an important clinical issue? J Nucl Med 1994;35(suppl):4S-7S.
21. Bolli R. Mechanism of myocardial "stunning." Circulation 1990:82:723-38.
22. Bolli R, Jeroudi M, Patel B, et al. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion: evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ Res 1989:65:607-22.
23. Bolli R, Zhu W, Thornby J, O'Neill P, Roberts R. Time-course and determinants of recovery of function after reversible ischemia in conscious dogs. Am J Physiol 1988;254:H102-14.
24. Marban E. Myocardial stunning and hibernation: the physiology behind the colloquialisms. Circulation 1991;83:681-8.
25. 2+ activation of contraction as a consequence of reperfusion-induced calcium overload in ferret heart. J Clin Invest 1987;79:950-61.
26. Greenfield R, Swain J. Disruption of myofibrillar energy use: dual mechanisms that may contribute to postischemic dysfunction in stunned myocardium. Circ Res 1987;60:283-9.
27. Kraus S, Jacobus W, Becker L. Alterations in sarcoplasmic reticulum calcium transport in the postischemic "stunned" myocardium. Circ Res 1989;65:526-30.
28. Bolli R. Oxygen-derived free radicals and postischemic myocardial dysfunction ("stunned myocardium"). J Am Coll Cardiol 1988;12:239-49.
29. McCord J. Oxygen-derived free radicals in postischemic tissue. N Engl J Med 1985;312:159-63.
30. Przyldenk K, Kloner R. Superoxide dismutase plus catalase improve contractile function in the canine model of "stunned myocardium." Circ Res 1986:58:148-56.
31. Engler R, Cowell J. Granulocytes cause reperfusion ventricular dysfunction after 15-minute ischemia in the dog. Circ Res 1987;61:20-8.
32. Zhao M, Zhang H, Robinson T, Factor S, Sonnenblick E, Eng C. Profound structural alterations of the extracellular collagen matrix in postischemic dysfunction ("stunned") but viable myocardium. J Am Coll Cardiol 1987;10:1322-34.
33. Bolli R, Zhu W, Myers M, Hartley C, Robert R. Beta-adrenergic stimulation reverses postischemic myocardial dysfunction without producing subsequent functional deterioration. Am J Cardiol 1985:56:964-8.
34. Becker L, Levine J, DiPaula A, Guarnieri T, Aversano T. Reversal of dysfunction in postischemic stunned myocardium by epinephrine and postextrasystolic potentiation. J Am Coll Cardiol 1986:7:580-9.
35. Dyke S, Urschel C, Sonnenblick E, Gorlin R, Cohn P. Detection of latent function in acutely ischemic myocardium in the dog: comparison of pharmacologie stimulation and postextrasystolic potentiation. Circ Res 1975;36:490-7.
36. Ellis S, Wynne J, Braunwald E, Henschke C. Sandor T, Kloner R. Response of reperfusion-salvaged, stunned myocardium to inotropic stimulation. Am Heart J 1984:107:13-9.
37. Jeroudi M, Cheirif J, Habib G, Bolli R. Prolonged wall motion abnormalities aller chest pain at rest in patients with unstable angina: a possible manifestation of myocardial stunning. Am Heart J 1994:127:1241-50.
38. Nixon J, Brown C, Smitherman T. Identification of transient and persistent wall motion abnormalities in patients with unstable angina by twodimensional echocardiography. Circulation 1982:65:1497-1503.
39. Renkin J, Wijns W, Ladha Z, Col J. Reversal of segmental hypokinesis by coronary angioplasty in patients with unstable angina, persistent T wave inversion, and left anterior descending coronary artery stenosis: additional evidence for myocardial stunning. Circulation 1990:82:913-21.
40. 18Ffluorodeoxyglucose in postischemic myocardium of patients with exerciseinduced angina. Circulation 1986:74:81-8.
41. Kloner R, Allen J, Cox T, Zheng Y, Ruiz C. Stunned left ventricular myocardium after exercise treadmill testing in coronary artery disease. Am J Cardiol 1991:68:329-34.
42. Apstein C, Deckelbaum L, Mueller M, Hagopian L, Hood WJ. Graded global ischemia and reperfusion: cardiac function and lactate metabolism. Circulation 1977:55:864-72.
43. Apstein C. Deckelbaum L, Hagopian L. Hood WJ. Acute cardiac ischemia and reperfusion: contractility, relaxation, and glycolysis. Am J Physiol 1978:235:11637-48.
44. Canty JJ, Klocke F. Reductions in regional myocardial function at rest in conscious dogs with chronically reduced regional coronary artery pressure. Circ Res 1987:61(suppl II):107-16.
45. Marshall R. Zhang D. Correlation of contractile dysfunction with oxidative energy production and tissue high energy phosphate stores during partial coronary flow disruption in the rabbit heart. J Clin Invest 1988:82:86-95.
46. Opie L. Coronary flow rate and perfusion pressure as determinants of mechanical function and oxidative metabolism of isolated perfused rat heart. J Physiol 1965:180:529-41.
47. Schulz R, Guth B, Pieper K, Martin C, Heusch C. Recruitment of an inotropic reserve in moderately ischemic myocardium at the expense of metabolic recovery: a model of short term hibernation. Circ Res 1992;70:1282-95.
48. Schulz R, Rose J, Martin C, Brodde O, Heusch G. Development of shortterm myocardial hibernation: its limitation by the severity of ischemia and inotropic stimulation. Circulation 1993:88:684-95.
49. Wier W, Yue D. Intracellular calcium transients underlying the short-term force-interval relationship in ferret ventricular myocardium. J Physiol (Lond) 1986:376:507-30.
50. Vanoverschelde J, Janier M, Bakke J, Marshall D, Bergmann S. Rate of glycolysis during ischemia determines extent of ischemic injury and functional recovery after reperfusion. Am J Physiol 1994;267:Hl 785-94.
51. Kitakaze M. Marban E. Cellular mechanism of the modulation of contractile function by coronary perfusion pressure in ferret hearts. J Physiol (Lond) 1989:414:455-72.
52. Maes A, Flameng W, Nuyts J, et al. Histological alterations in chronically hypoperfused myocardium: correlation with PET findings. Circulation 1994:90:735-45.
53. Vanoverschelde J, Wijns W, Depre C, Essamri B, Heyndrickx G, Borgers M. Mechanisms of chronic regional postischemic dysfunction in humans: new insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993;87:1513-23.
54. Bolukoglu H, Liedtke A, Nellis S, Eggelston A, Subramaniam R, Renstrom B. An animal model of chronic coronary stenosis resulting in hibernating myocardium. Am J Physiol 1992;263:H20-9.
55. Buxton D. Dysfunction in collateral-dependent myocardium: hibernation or repetitive stunning? Circulation 1993:87:1756-8.
56. Brundage B, Massie B, Botvinick E. Improved regional ventricular function after successful surgical revascularization. J Am Coll Cardiol 1984;3:9028.
57. Rozanski A, Bernard D, Gray R, et al. Preoperative prediction of reversible myocardial asynergy by postexercise radionuclide ventriculography. N Engl J Med 1982:307:212-3.
58. Bonow R. The hibernating myocardium: implications for management of congestive heart failure. Am J Cardiol 1995;75:17A-25A.
59. Di Carli M, Davidson M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994:73:527-33.
60. Camici P, Ferrannini E, Opie L. Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis 1989;32:217-38.
61. Opie L. Effects of regional ischemia on metabolism of glucose and fatty acids: relative rates of aerobic and anaerobic energy production during myocardial infarction and comparison with effects of anoxia. Circ Res 1976;38(suppl I):I-52-74.
62. Schelbert H. Metabolic imaging to assess myocardial viability. J Nucl Med 1994;35(suppl):8S-14S.
63. Schelbert H, Buxton D. Insights into coronary artery disease gained from metabolic imaging. Circulation 1988;78:496-505.
64. Bonow R, Berman D, Gibbons R, et al. Cardiac positron emission tomography: a report for health professionals from the Committee on Advanced Cardiac Imaging and Technology of the Council on Clinical Cardiology, American Heart Association. Circulation 1991;84:447-54.
65. Schelbert H, Bonow R, Geltman E, Maddahi J, Schwaiger M. Clinical use of positron emission tomography: position paper of the Cardiovascular Council of the Society of Nuclear Medicine. J Nucl Med 1993;34:1385-8.
66. Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64:860-5.
67. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-8.
68. Marshall R, Tillisch J, Phelps M, et al. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography F-18-labeled fluorodeoxyglucose and N-13 ammonia. Circulation 1983:67:766-78.
69. Brunken R, Tillisch J, Schwaiger M, et al. Regional perfusion, glucose metabolism, and wall motion in patients with chronic electrocardiographic Q wave infarctions: evidence for persistence of viable tissue in some infarct regions by positron emission tomography. Circulation 1986;73:951-63.
70. Fudo T. Kambara H. Hashimoto T, et al. E-18 deoxyglucose and stress N-13 ammonia positron omission tomography in anterior wall healed myocardial infarction. Am J Cardiol 1988:61:1191-7.
71. Gropler R, Gellman E, Sampathkumaran K. el al. Functional recovery after coronary revascularization tor chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol 1992:20:569-77.
72. Lucignani C, Paolini G. Landoni C. et al. Fresnrgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2methoxyisobutylisonitrile single photon emission tomography and fluorino18 tluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur I Nucl Med 1992:19:874-81.
73. Carrel f, Jenni R. Haubold-Reuter S, Von Schnlthess G, Pasic M, l'urina M. Improvement in severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg 1992:6:479-84.
74. vom Dahl J, Altehoefer C, Sheehan K et al. Recovery of myocardial function following coronary revascularization: impact of viability and long-term vessel patency as assessed by preoperative F-18 FDC PET and serial angiography [Abstract]. J Nucl Med 1993:34:23P.
75. vom Dahl J. Eilzman D, Al-Aouar Z. et al. Relation of regional function, perfusion, and metabolism in patients with advanced coronary artery disease undergoing surgical revascularization. Circulation 1994:90:2356-66.
76. Bessozi M, Brown M, Hubner K. et al. Retrospective post-therapy evaluation of cardiac function in 208 coronary artery disease patients evaluated by positron emission tomography (Abstract). J Nucl Med 1992:33:885.
77. Depre C. Melin J, Vanoverschelde J, Borgers M, Wijns W. Assessment of myocardial viability after bypass surgery by pre-operalive PET flowmetabolism measurements and ultrastructural analysis of myocardial biopsies [Abstract]. Circulation 1993:88:1-199.
78. Neinaber C, Drunken R, Sherman C. et al. Metabolic and functional recovery of ischemic human myocardium after coronary angioplasty. J Am Coll Cardiol 1991:18:966-78.
79. Eilzman D, Al-Aouar Z, Kanter H. et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992:20:559-65.
80. Di Carli M, Davidson M, Eittle R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am I Cardiol 1994:73:527-33.
81. Tacgtmeyer H, Roberts A, Raine A. Energy metabolism in reperfused heart muscle: metabolic correlates of return of function. J Am Coll Cardiol 1985:6:864-70.
82. Vanoverschelde J, Melin J, Bol A, et al. Regional oxidative metabolism in patients after recovery from reperfused anterior myocardial infarction: relation to regional blood flow and glucose uptake. Circulation 1992:85:921.
83. Groplor K. Siegel B. Sampathkumaran K. et al. Dopendonco of recovery of contractile function on maintenance of oxidative metabolism after myocardial infarction. J Am Coll Cardiol 1992:20:569-77.
84. Melin J, Vanoverscholde I, Bol A, Heyndrickx C, Wijns W. The use of carbon 11-labeled acetate for assessment of aerobic metabolism. J Nucl Cardiol 1994:1:848-57.
85. Pierard L, De Lansheere C, Berthe C, Rigo P, Kulbertus H. Identification of viable myocardium by echocardiography during dobutamine infusion in patients with myocardial infarction after thrombolytic therapy: comparison with positron emission tomography. J Am Coll Cardiol 1990:15:1021-31.
86. Schwaiger M, Brunken R, Grover-McKay M, et al. Regional myocardial metabolism in patients with acute myocardial infarction assessed by positron emission tomography. J Am Coll Cardiol 1986:8:800-8.
87. Yamamoto Y, de Suva R, Rhodes C, et al. A new strategy for the assessment of viable myocardium and regional myocardial blood flow using O-15 water and dynamic positron emission tomography. Circulation 1992:86:167-78.
88. de Suva R, Yamamoto Y, Rhodes C, et al. Preoperative prediction of the outcome of coronary revascularization using positron emission tomography. Circulation 1992:86:1738-42.
89. Gould K, Yoshida K, Hess M, Haynie M, Mullani N, Smalling R. Myocardial metabolism of fluorodeoxyglucose compared to cell membrane integrity for the potassium analogue rubidium-82 for assessing infarct size in man. J Nucl Med 1991:32:1-9.
90. Dahlberg S, Leppo J. Myocardial kinetics of radiolabeled perfusion agents: basis for perfusion imaging. J Nucl Cardiol 1994;1:189-97.
91. Sinusas A, Watson D, Cannon J, Beller G. Effect of ischemia and post ischemic dysfunction on myocardial uptake of technetium-99m-labelled methoxyisobutyl isonitrile and thallium 201. J Am Coll Cardiol 1989;14:1785-93.
92. Granato J, Watson D, Flanagan T, Beller G. Myocardial thallium-201 kinetics and regional flow alterations with 3 hours of coronary occlusion and either rapid reperfusion through a totally patent vessel or slow reperfusion through a critical stenosis. J Am Coll Cardiol 1987:9:109-15.
93. Moore C, Cannon J, Watson D, et al. Thallium-201 kinetics in stunned myocardium characterized by severe postischemic systolic dysfunction. Circulation 1990;81:1622-32.
94. Granato J, Watson D, Flanagan T, Gascho J, Beller G. Myocardial thallium201 kinetics during coronary occlusion and reperfusion: influence of method of reflow and thallium administration. Circulation 1986;73:150-62.
95. Melin J, Becker L, Bulkey B. Difference in thallium-201 uptake in reperfused and non-reperfused myocardial infarction. Circ Res 1983:53:414-9.
96. Pohost G, Zir L, Moore R, et al. Differentiation of transiently ischemic myocardium from infarcted myocardium by serial imaging after a single dose of thallium-201. Circulation 1977;55:294-302.
97. Iskandrian A, Hakki A, Kane S, et al. Rest and redistribution thallium-201 myocardial scintigraphy to predict improvement in left ventricular function after coronary arterial bypass grafting. Am J Cardiol 1983:51:1312-16.
98. Berger B, Watson D, Burwell L, et al. Redistribution of thallium at rest in patients with stable and unstable angina and the effect of coronary artery bypass surgery. Circulation 1979;60:1114-25.
99. Blood D, McCarthy D, Sciacca R, et al. Comparison of single dose and double dose thallium-201 myocardial perfusion scintigraphy for the detection of coronary artery disease and prior myocardial infarction. Circulation 1978:58:777-88.
100. Brunken R, Schwaiger M, Grover-McKay M, Phelps M, Tillisch J, Schelbert H. Positron emission tomography detects tissue metabolic activity in myocardial segments with persistent thallium perfusion defects. J Am Coll Cardiol 1987:10:557-67.
101. Tamaki N, Yonekura Y, Yaniashila K, et al. Relation of left ventricular perfusion and wall motion with metabolic activity in persistent defects on thallium-201 tomography in healed myocardial infarction. Am J Cardiol 1988:62:202-8.
102. Manyari D. Knudtson M Kloiber R. Roth D. Sequential thallium-201 myocardial perfusion studies after successful percutaneous transluminal coronary angioplasly: delayed resolution of exercise induced scintigraphic abnormalities. Circulation 1988:77:86-95.
103. Liu P, Kiess M, Okada R, et al. The persistent defect on exercise thallium imaging and its fate after myocardial revascularization: does it represent scar or ischemia? Am Heart J 1985:110:991-1001.
104. Gibson R, Watson D, Taylor G, et al. Prospective assessment of regional myocardial perfusion before and after coronary revascularization surgery by quantitative lhallium-201 scintigraphy. J Am Goll Gardiol 1983:1:804-15.
105. Gutman J, Berman D. Freeman M, et al. Time to complete redistribution of thallium-201 in exercise myocardial scintigraphv: relationship to the degree of coronary stenosis. Am Heart J 1983:106:989-95.
106. Ohtani H, Tamaki N, Yonekura Y, et al. Value of thallium-201 reinjection after delayed SPKCT imaging for predicting reversible ischemia after coronary artery bypass grafting. Am 1 Cardiol 1990:66:394-9.
107. Marin-Nelo J, Dilsizian V, Arrighi 1. et al. Thallium reinjeclion demonstrates viable myocardium in regions with reverse redistribution. Circulation 1993:88(part 1):1 736-45.
108. Soufer R, Dey H. Lawson A, Wackers F. Zaret B. Relationship between reverse redistribution on planar thallium scintigraphv and regional myocardial viability: a correlative PET study. 1 Nucl Med 1995:36:180-7.
109. Ohte N. Hahimimoto T, Banno T. et al. Clinical significance of reverse redistribution on 24 hour delayed imaging of exercise thallium-201 myocarriial SPKCT: comparison with myocardial fluorine-18-FDG-PET imaging and left ventricular wall motion. J Nucl Med 1995:36:86-92.
110. Kiat H. Berman D. Maddahi J, et al. Late reversibility of tomographic myocarriial lhallium-201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol 1988:12:1456-63.
111. Yang L, Berman D. Kiat H, el al. The frequency of late reversibility in SPECT thallium-201 stress-redistribution studies. 1 Am Coll Cardiol 1989:15:334-40.
112. BnmkenR, Mody F Hawkins R, NienaberC. Pbelps M. Schelbert H. Positron emission tomography detects metabolic viability in myocardium with persistent 24-hour single photon emission computed tomography Tl-201 defects. Circulation 1992:86:1357-69.
113. Kayden D. Sigal S, Soufer R. Maltera J. Zaret B. Wackers FJ. Thallium-201 for assessment of myocardial viability: quantitative comparison of 24-hour redistribution imaging with imaging after reinjeotion at rest. J Am Coll Cardiol 1991:18:1480-6.
114. Kiat H, Williams C. Wang F et al. Late redistribution Tl-201/stress Tc-99m seslamibi separate acquisition dual isotope myocardial perfusion SPECT: a feasibility study [Abstract]. J Am Coll Cardiol 1995:(special issue):215A.
115. Dilsizian V. Rocco T. Freedman N, Leon MB, Bonow R. Enhanced detection of ischémie but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990:323:141-6.
116. Rocco T. Dilsizian V. Strauss H. Boucher C. Technetium-99m isonitrile myocardial uptake at rest: II. Relation to clinical markers of potential viability. J Am Coll Cardiol 1989:14:1678-84.
117. Tamaki N, Ohtani H, Yoshiharu Y, et al. Significance of fill-in after thallium201 reinjection following delayed imaging: comparison with regional wall motion and angiographie findings. J Nucl Med 1990:31:1617-23.
118. Tamaki N, Ohtani H, Yamashita K, et al. Metabolic activity in the areas of new fill-in after thallium-201 reinjection; comparison with positron emission tomography using fluorine-18-deoxyglucose. J Nucl Med 1991;83:1247-55.
119. Inglese E, Brambilia M, Dondi M, et al. Assessment of myocardial viability after thallium-201 reinjection or rest-redistribution imaging: a multicenter study. J Nucl Med 1995;36:555-63.
120. Nienaber C, de la Roche J, Carnarius H, Montz R. Impact of thallium-201 reinjection imaging to identify myocardial viability after vasodilationredistribution SPECT [Abstract]. J Am Coll Cardiol 1993;21:283A.
121. Bonow R, Dilsizian V, Cuocolo A, Bacharach S. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction: comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose. Circulation 1991;83:26-37.
122. Perrone-Filardi P, Bacharach S, Dilsizian V, Maurea S, Frank J, Bonow R. Regional left ventricular wall thickening: relation to regional uptake of F-18fluorodeoxyglucose and thallium-201 in patients with chronic coronary artery disease and left ventricular dysfunction. Circulation 1992;86:1125-37.
123. Wackers F. The maze of myocardial perfusion imaging protocols in 1994. J Nucl Cardiol 1994;1:180-8.
124. Dilsizian V, Bonow R. Differential uptake and apparent thallium-201 "washout" after thallium reinjection: options regarding early redistribution imaging before reinjection or late redistribution imaging after reinjection. Circulation 1992:85:1032-8.
125. Dilsizian V, Smeltzer W, Freedmen N, Dextras R, Bonow R. Thallium reinjection after stress-redistribution imaging: does 24-hour delayed imaging after reinjection enhance detection of viable myocardium? Circulation 1991;83:1247-55.
126. Kiat H, Friedman J, Wang F, et al. Frequency of late reversibility in stressredistribution thallium-201 SPECT using an early reinjection protocol. Am Heart J 1991;122:613-9.
127. van Eck-Smit B, van der Wall E, Kuijper A, Zwinderman A, Pauwels E. Immediate thallium-201 reinjection following stress imaging: a time-saving approach for detection of myocardial viability. J Nucl Med 1993:34:737-43.
128. Dilsizian V, Freedman N, Bacharach S, Perrone-Filardi P, Bonow R. Regional thallium uptake in irreversible defects: magnitude of change in thallium activity after reinjection distinguishes viable form nonviable myocardium. Circulation 1992;85:627-34.
129. Gewirtz H, Beller G, Strauss H, et al. Transient defects of resting thallium scans in patients with coronary artery disease. Circulation 1979:59:707-13.
130. Mori T, Minamiji K, Kurogane H, Ogawa K, Yoshida Y. Rest-injected thallium201 imaging for assessing viability of severe asynergic regions. J Nucl Med 1991:32:1718-24.
131. Takemoto K, Kiat H, Friedman J, et al. The frequency of late redistribution in rest thallium-201 scintigraphic studies. Circulation 1993;88:941-9.
132. Dilsizian V, Perrone-Filardi P, Arrighi J, et al. Concordance and discordance between stress-redistribution-reinjection and rest-redistribution thallium imaging for assessing viable myocardium: comparison with metabolic activity by PET. Circulation 1993:88:941-52.
133. Ragosla M. Heller G. Watson D, Kaul S, Gimple L. Quantitative planar restredistribution Tl-201 imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary artery bypass surgery in patients with severely depressed left ventricular function. Circulation 1993:87:1030-41.
134. Udelson J, Coleman P, Melherall 1. el al. Predicting recovery of severe ventricular dysfunction: comparison of resting scinligraphy with thallium201 and Tc-99m sestamibi. Circulation 1994:89:2552-61.
135. Perrone-Filardi P. Pace L. Prastaro M. et al. Dobutamine echocardiography predicts improvement of hypoperfused dysfunctional myocardium after revascnlarization in patients with coronary artery disease. Circulation 1995:91:2556-05.
136. Lomboy C. Schnlman D. Grill H, Flores A. Orie J, Granalo J. Restredistribution thallium-201 scintigraphy to determine myocardial viability early after myocardial infarction. J Am Coll Cardiol 1995:25:210-7.
137. Gioia G. Powers J, Heo J. Iskandrian A. Prognostic: value of rest-redistribution tomographic thallium-201 imaging in ischemic cardiomyopathy. Am J Cardiol 1995:75:759-02.
138. Burns R, Galligan L, Wright L. Thallium infusion scintigraphy improves detection of viable myocardium [Abstract]. Circulation 1990:82(suppl III):III-544.
139. Tartagni F. Fallani E, Corbelli C. et al. Detecting hibernating myocardium with SPECT and lhallium-glucose-insulin infusion. J Nucl Med 1995:30:1377-83.
140. Permutter X. Wilson R. Angello D, et al. Ribose facilitates thallium-201 redistribution in patients with coronary artery disease. J Nucl Med 1991:32:193-200.
141. Hendel R. Vansanl J. Wilson R, Sonnemaker R, Lally R, Hoff J. The use of Dribose in conjunction with Tl-201 perfusion imaging for identification of reversible perfusion abnormalities: results of a placebo-controlled, double blinded trial [Abstract]. Circulation 1995:92:1447.
142. He Z. Darcourt J. Cuignier A. el al. Nitrates improve detection of ischemic but viable myocardium by lhallium-201 reinjection SPFCT. J Nucl Med 1993:34:1472-7.
143. Medrano R. Mahmarian 1. Ashmore R. et al. The enhanced detection of myocardial viability with thallium-201 reinjection after nitroglycerine: a randomized. double blind, placebo controlled trial using quantitative tomography [Abstract]. Circulation 1992:8G(suppl I):I-109.
144. Medrano R. Mahmarian J. Verani M. Nitroglycerine before injection of thallium-201 enhances detection of reversible hypoperfusion via collateral blood flow: a randomized. double blind parallel, placebo-controlled trial using quantitative tomography [Abstract]. I Am Coll Cardiol 1993:21:221 A.
145. Bodenheimer M. Banka V, Hermann G. et al. Reversible asynergy: histopathologic and electrocardiographs: correlations in patients with coronary artery disease. Circulation 1970:553:792-0.
146. Zaacks's, Parker M, Vardi C. McCarthy W. Bonow R, Hendel R. Does reinjection thallium imaging provide supplemental value lor risk stratification in vascular surgery patients when compared with stress/ redistribution thallium scintigraphy? Circulation 1994:90:1-103.
147. Zaret B. Wackers F Nuclear cardiology. N Fngl J Med 1993:329:775-83, 855-03.
148. Sporn V. Balino N. Holman L. et al. Simultaneous measurement of ventricular lunclion and myocardial perfusion using lechnelium-99m isonitriles. Clin Nucl Med 1988:13:77-81.
149. Villanueva-Meyer J, Mena I, Harahara K. Simultaneous assessment of left ventricular wall motion and myocardial perfusion with technetium-99mmethoxy isobutyl isonitrile at stress and rest in patients with angina: comparison with thallium-201 SPECT. J Nucl Med 1990:31:457-63.
150. Najm Y, Maisey M, Ellam S, Minstry R, Curry P, Sowton E. The evaluation of ventricular function using gated myocardial imaging with Tc-99m MIBI. Eur Heart J 1989;10:142-8.
151. Mannting F, Morgan-Mannting M. Gated SPECT with technetium-99msestamibi for assessment of myocardial perfusion abnormalities. J Nucl Med 1993;34:601-8.
152. Chua T, Kiat H, Germano G, et al. Gated technetium-99m sestamibi for simultaneous assessment of stress myocardial perfusion, postexercise regional ventricular function and myocardial viability; correlation with echocardiography and rest thallium scintigraphy. J Am Coll Cardiol 1994;23:1107-14.
153. DePuey E, Rozanski A. Using gated technetium-99m-sestamibi SPECT to characterize fixed myocardial defects as infarct or artifacts. J Nucl Med 1995:36:952-5.
154. Iskandrian A, Heo J, Kong B, Lyons E, Marsch S. Use of technetium-99m isonitrile (RP30A) in assessing left ventricular perfusion and function at rest and during exercise in coronary artery disease, and comparison with coronary arteriography and exercise thallium-201 SPECT imaging. Am J Cardiol 1989;64:270-5.
155. Wackers F, Berman D, Maddahi J, et al. Technetium-99m hexakis 2 methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989:30:301-11.
156. Beanlands R, Dawood F, Wen W, et al. Are the kinetics of technetium-99m methoxyisobutyl isonitrile affected by cell metabolism and viability? Circulation 1990;82:1802-14.
157. Okada R, Glover D, Gaffney T, et al. Myocardial kinetics of technetium99m hexakis-2-methoxy-2-methylpropyl-isonitrile. Circulation 1988;77:4918.
158. Freeman I, Grunwald A, Hoory S, Bodenheimer M. Effect of coronary occlusion and myocardial viability on myocardial activity of technetium99m-sestamibi. J Nucl Med 1991:32:292-8.
159. Piwinca-Worms D, Kronauge J, Chin M. Uptake and retention of hexakis (2methylisobutyl isonitrile) technetium (I) in cultured chick myocardial cells: mitochondrial and plasm membrane potential dependence. Circulation 1990:82:1826-38.
160. Beller G, Glover D, Edwards N, Ruiz M, Simanis J, Watson D. Tc-99msestamibi uptake and retention during myocardial ischemia and reperfusion. Circulation 1993;87:2033-42.
161. Sansoy V, Glover D, Watson D, et al. Comparison of thallium-201 resting redistribution with technetium-99m-sestamibi uptake and functional response to dobutamine for assessment of myocardial viability. Circulation 1995:92:994-1004.
162. Dilsizian V, Arrighi J, Diodati J, et al. Myocardial viability in patients with chronic coronary artery disease: comparison of Tc-99m-sestamibi with thallium reinjection and F-18 fluorodeoxyglucose. Circulation 1994;89:578-87.
163. Li S, Liu X, Lu Z, et al. Assessment of myocardial viability using Tc-99mMIBI myocardial SPECT. Med Rev 1994:48:36-41.
164. Soufer R, Dey H. Ng C. Zaret B. Comparison of sestamibi single-photon omission computed tomography for estimating left ventricular myocardial viability. Am J Cardiol 1995:75:1214-9.
165. Ceon A, Eisner K, Martin S. et al. Comparison of single-photon emission computed tomographic (SPECT) myocardial perfusion imaging with thallium-201 and technetinm-99m sestamibi in dogs. J Am Coll Cardiol 1992:20:1612-25.
166. Maurea S, Cuolo A, Pace L, Nicolai E. Nappi A, Imbriaco M. Left ventricular dysfunction in coronary artery disease: comparison between restredistribution lhallium-201 and resting tochnetium-99m methoxyisobutyl isonitrilo imaging. J Nucl Cardiol 1994:1:65-72.
167. Marzullo P, Sambuceti G, Parodi O. The role of sestamibi scintigraphy in (he radioisotopic assessment of myocardial viability. J Nucl Med 1992:33:1925-30.
168. Marzullo P, Parodi O, Roisonhofer B, et al. Value of rest thallium-201/ technetium-99m sestamibi scans and dobutamine echocardiography for detecting myocardial viability. Am J Cardiol 1993;71:166-72.
169. Cuocolo A, Pace L, Ricciardelli B, Chiariello M, Trimarco B, Salvalore M. Identification ol viable myocardium in patients with chronic coronary artery disease: comparison of thallium-201 scintigraphy with reinjection and technetium-99m methoxyisobutyl isonitrile. J Nucl Med 1992;33:505-11.
170. Sawada S. Allman K, Muzik O, et al. Positron emission tomography defects evidence of viability in rest lechnetium-99m sestamibi defects. J Am Coll Cardiol 1994:23:92-8.
171. Maublant J. Citron B, Lipiocki J. et al. Rost technetium 99m-sestamibi tomoscintigraphv in hibernating myocardium. Am Heart J 1995:129:306-14.
172. Leavitt 1. Better N. Tow D, Rocco T. Demonstration of viable, stunned myocardium with technetium-99m-sestamibi. J Nucl Med 1994:35:1805-7.
173. Wackers F, Gibbons R. Verani M, et al. Serial quantitative planar Tc-99m isonitrile imaging in acute myocarriial infarction: efficacy for non-invasive assessment of thrornholytic therapv. J Am Coll Cardiol 1989:14:861-73.
174. Verani M. Jeroudi M. Mahmarian J, et al. Quantification of myocardial infarction during coronary occlusion and myocardial salvage after reperfusion using cardiac imaging with technetium-99m hexakis 2-methoxybutyl isonitrile. J Am Coll Cardiol 1988:12:1573-81.
175. Gibbons R, Vorani M. Behrenbeck T. et al. Feasibility of tomographic technetium-99ni-hexakis-2-methoxy-2-methvlpropyl-isonilrile imaging for the assessment of myocardial area at risk and the effect of acute treatment in myocardial infarction. Circulation 1989:80:1277-86.
176. Pellikka P. Behrenbeck T. Verani M, Mahmarian J, Wackers F, Gibbons R. Serial changes in myocardial perfusion using tomographic technetium-99mhexakis-2-metlioxy-2-methylpropyl-isonilrile imaging following reperfusion therapy of myocardial infarction. 1 Nucl Meri 1990:31:1269-75.
177. Altehoefer C. Kaiser H, Dorr R. et al. Fluorine-18 deoxyglucose PET for assessment of viable myocardium in perfusion defects in 99mTc MIBI SPECT: a comparative study in patients wilh coronary artery disease. Eur J Nucl Med 1992:19:334-42.
178. von Dahl 1. Altehoefer C. Biedermann M, Uebis R, Buell U, Hanrath P. Technetiiim-99ni melhoxy-isobutvl isonitriles as a tracer of myocardial viability: a quantitative comparison with F-18 fluorodeoxyglucose in 100 patients with coronary artery disease [Abstract]. J Am Coll Cardiol 1993:2 1:283A.
179. Palmas W, Friedman J, Diamond G, Silber H, Kiat H, Berman D. Incremental value of simultaneous assessment of myocardial function and perfusion with technetium-99m sestamibi for prediction of extent of coronary artery disease. J Am Coll Cardiol 1995;25:1024-31.
180. Quaife R, Corbett J. The presence of segmental thickening by gated sestamibi SPECT predicts rest Tl-201 segmental viability [Abstract]. Circulation 1994;90:I-11.
181. Giubbini R, Milan E, Zoccarato O, et al. Does 99m Tc sestamibi gated-SPECT provide additional information over ungated-sestamibi and 201-T1 reinjection imaging in viability assessment [Abstract]. J Am Coll Cardiol 1995;(special issue):341A.
182. Berman D, Kiat H, Friedman J, et al. Separate acquisition rest thallium-201/ stress technetium-99m sestamibi dual-isotope myocardial perfusion single photon emission computed tomography: a clinical validation study. J Am Coll Cardiol 1993:22:1455-64.
183. Maublant J, Marcaggi X, Lusson J, et al. Comparison between thallium-201 and technetium-99m methoxyisobutyl isonitrile defect size in single-photon computed tomography at rest, exercise and redistribution in coronary artery disease. Am J Cardiol 1992:69:183-7.
184. Worsley D, Fung A, Burns R. Identification of viable myocardium with technetium-99m-MIBI infusion. J Nucl Med 1995:36:1037-9.
185. Galli M, Marcassa C, Imparato A, Campini R, Orrego P, Giannuzzi P. Effects of nitroglycerine by technetium-99m sestamibi tomoscintigraphy on resting regional myocardial hypoperfusion in stable patients with healed myocardial infarction. Am J Cardiol 1994:74:843-8.
186. Bisi G, Sciagra R, Santoro G, Fazzini P. Rest technetium-99m sestamibi tomography in combination with short-term administration of nitrates: feasibility and reliability for prediction of postrevascularization outcome of asynergic territories. J Am Coll Cardiol 1994:24:1282-9.
187. Gray W, Gewirtz H. Comparison of Tc-99m-teboroxime with thallium for myocardial imaging in the presence of a coronary artery stenosis. Circulation 1991:84:1796-1807.
188. Stewart R, Schwaiger M, Hutchins G, et al. Myocardial clearance kinetics of technetium-99m SQ30217: a marker of regional myocardial blood flow. J Nucl Med 1990:31:1183-90.
189. Hendel R, McSherry B, Leppo J. Comparison of teboroxime and thallium for the reversibility of exercised-induced myocardial perfusion defects. Am Heart J 1993:126:856-62.
190. Links J, Frank T, Becker L. Effect of differential tracer washout during SPECT acquisition. J Nucl Med 1991:32:2253-7.
191. Johnson L, Seldin D. Clinical experience with technetium-99m teboroxime, a neutral lipophilic myocardial perfusion imaging agent. Am J Cardiol 1990;66:63E-7E.
192. Bisi G, Sciagra, Santoro G, Zerauschek F, Fazzini P. Sublingual isosorbide dinitrate to improve technetium-99m-teboroxime perfusion defect reversibility. J Nucl Med 1994:35:1274-8.
193. Zaret B, Rigo P, Wackers F, et al. Myocardial perfusion imaging with technetium-99m tetrofosmin: comparison to thallium-201 imaging and coronary angiography in a Phase III multicenter trial. Circulation 1995:91:313-9.
194. Hendel R, Gerson M, Verani M, et al. Perfusion imaging with Tc-99m furifosmin (Q12): multicenter Phase III trial to evaluate safety and comparative efficacy [Abstract]. Circulation 1994;90:I-449.
195. Tamaki N, Takahashi N, Kawamoto M, et al. Myocardial tomography using fechnetium-99m tetrofosmin to evaluate coronary artery disease. J Nucl Med 1994:35:594-600.
196. Lenihan D, Gerson M, Gabel M, Huth G, McGoron A, Walsh R. Influence of stunned hut viahle myocardium on Q12 and thallium uptake after reperfusion in canine mvocardial infarction [Abstract]. Circulation 1995:92:1-798.
197. Pasqualini R, Duatti A, Bellande E, et al. Bis (dithiocarbamato) nitrido technetium-99m radiopharmaceulicals: a class of neutral mvocardial imaging agents. J Nucl Med 1994:35:334-41.
198. Murray G, Schad N, Ladd W, et al. Metabolic cardiac imaging in coronary artery disease with severe left ventricular dysfunction: assessment of myocardial viability with 1-123-iodophenylpentadecanoic acid imaged by a multicrvstal camera and correlation with transmural myocardial biopsy. J Nucl Med 1992:33:1269-77.
199. Reske S. Experimental and clinical experience with iodine 123-labeled iodophenylpenladecanoic acid in cardiology. 1 Nucl Gardiol 1994:1:858-64.
200. Nishimura T, Umehara F, Shimonagata T, Nagata S, Haze K. Clinical results with beta-methyl-/)-(123I)iodophenylpentadecanoic acid, single-photon emission computed tomography in cardiac disease. J Nucl Cardiol 1994:1:865-71.
201. Hansen C, Gorbertl J, Pippin J, et al. Iodine-123-iodophenylpentadecanoic acid and single-photon emission computed tomography in identifying left ventricular regional metabolic abnormalities in patients with coronary artery disease: comparison with thallium-201 myocardial tomography. J Am Coll Gardiol 1988:12:78-87.
202. Pippin J. Corbett J, Jansen D, et al. Comparison of I-123 iodophenylpentadecanoic acid and thallium-201 tomographic imaging for the detection of coronary artery stenoses. Circulation 1987:76:IV-508.
203. Corbett J. Clinical experience with iodine-123-iodophenylpentadecanoic acid. J Nucl Med 1994;35[suppl]:328-7S.
204. Hansen C, Heo |, Van Decker W, Iskandrian A. Comparison of 1-123 phenylpentadecanoic acid with thallium-201 to predict functional recovery after coronary revasculamation [Abstract]. Circulation 1994:90:1-77.
205. Ugolini V, Hansen C, Kulkurni P, Jansen D, Akers M, Corhert J. Abnormal mvocardial fatty acid metabolism in dilated cardiomyopathy detected by iodine-123 phenypentadecanoic acid and tomographic imaging. Am J Gardiol 1988:62:923-8.
206. Tamaki N, Kawamolo M, Yonekura Y, et al. Regional metabolic abnormality in relation to perfusion and wall motion in patients with myocardial infarction: assessment with emission tomography using an iodinated branched fatty acid analog. J Nucl Med 1992:33:659-67.
207. Franken P, De Geeter F, Demoor D, Block P, Bossuyt A. Abnormal free fatty acid uptake in subacute myocardial infarction alter coronary thrombolysis: correlation with wall motion and inotropic reserve. J Nucl Med 1994:35:1758-65.
208. Marie P. Karcher G. Danchin N, et al. Thallium-201 rest-reinjection and indine-123-MlHA imaging of myocardial infarction: analysis of defect reversibility. J Nucl Med 1995:36:1561-8.
209. Williams K, Taillon L, Spark V. Quantitative; planar imaging of glucose metabolic activity in myocardial segments with exercise thallium-201 perfusion defects in patients with myocardial infarction: comparison with late (24 hr) redistribution in thallium imaging for detection of hibernating myocardium. Am Heart J 1992;124:294-304.
210. Burt R, Perkins O, Oppenheim B, et al. Direct comparison of fluorine-18FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J Nucl Med 1995;36:176-9.
211. Huitink J, Visser F, van Lingen A, et al. Feasibility of planar fluorine-18FDG imaging after recent myocardial infarction to assess myocardial viability. J Nucl Med 1995;36:975-81.
212. Leichner P, Morgan H, Holdeman K, et al. SPECT imaging of fluorine-18. J Nucl Med 1995:36:1472-5.
213. Martin W, Delbeke D, Patton J, et al. FDG-SPECT: correlation with FDGPET. 1995:36:988-95.
214. Sandler M, Videlefsky S, Delbeke D, et al. Evaluation of myocardial ischemia using a rest metabolism/stress perfusion protocol with fluorine-18 deoxyglucose/technetium-99m MIBI and dual-isotope simultaneousacquisition single-photon emission computed tomography. J Am Coll Cardiol 1995;26:870-8.
215. Bax J, Cornel J, Visser F, et al. Prediction of functional recovery after revascularization with F-18-fluorodeoxyglucose and single photon emission computed tomography [Abstract]. Circulation 1994:90:1-314.
216. Schultz R, Myazaki S, Thaulow E, et al. Consequences of regional inotropic stimulation of ischemic myocardium on regional blood flow and function in anesthetized swine. Circ Res 1989:64:1116-26.
217. Horn H, Teicholz L, Cohn P, et al. Augmentation of left ventricular contraction pattern in coronary artery disease by an inotropic catecholamine: the epinephrine ventriculogram. Circulation 1974:49:1063-71.
218. Dyke S, Cohn P, Gorlin R, et al. Detection of residual myocardial function in coronary artery disease using postextrasystolic potentiation. Circulation 1974:50:694-9.
219. Hamby R, Aintablian A, Wisoff G, et al. H. Response of the left ventricle in coronary artery disease to postextrasystolic potentiation. Circulation 1975:51:428-35.
220. Popio K, Gorlin R, Bechtel D, Levine J. Postextrasystolic potentiation as a predictor of potential myocardial viability: preoperative analysis compared with studies after coronary bypass surgery. Am J Cardiol 1977:39:944-53.
221. Cohn L, Collins J, Cohn P. Use of the augmented ejection fraction to select patients with severe left ventricular dysfunction for coronary revascularization. J Thorac Cardiovasc Surg 1976;72:835-40.
222. Nesto R, Cohn L, Collins J, et al. Inotropic reserve: a useful predictor of increased 5 year survival and improved postoperative left ventricular function in patients with coronary artery disease and reduced ejection fraction. Am J Cardiol 1982:50:39-44.
223. Leier C, Unverferth D, Kates R. The relationship between plasma dobutamine concentrations and cardiovascular responses in cardiac failure. Am J Med 1979:66:238-42.
224. Tuttle R, Pollock D, Todd G, et al. The effect of dobutamine on cardiac oxygen balance, regional blood flow and infarction severity after coronary artery narrowings in dogs. Circ Res 1977:41:357-64.
225. Willerson J, Hutton I, Watson J, Platt M, Templeton G. Influence of dobutamine on regional blood flow and ventricular performance during acute and chronic myocardial ischemia in dogs. Circulation 1976;53:828-33.
226. Barilla F, Gheorghiade M, Alam M, Khaja F, Goldstein S. Low dose dobutamine in patients with acute myocardial infarction identifies viable but not contractile myocardium and predicts the magnitude of improvement in wall motion abnormalities in response to coronary revascularization. Am Heart J 1991:122:1522-31.
227. Duchak J, Smart S, Wynsen J, Hellman R, Sagar K. Low dose dobutamine induced infarction zone wall thickening correlates with thallium by delayed SPECT imaging. Circulation 1992;86:l-384.
228. Smart S, Sawada S, Ryan T, et al. Low dose dobutamine echocardiography detects reversible dysfunction after thrombolytic therapy of acute myocardial infarction. Circulation 1993:88:405-15.
229. Previtali M, Poli A, Lanzarini L, Fetiveau R, Mussini A, Ferrario M. Dobutamine stress echocardiography for assessment of myocardial viability and ischemia in acute myocardial infarction treated with thrombolysis. Am J Cardiol 1993;72:124G-33G.
230. Watada H, Ito H, Oh H, et al. Dobutamine stress echocardiography predicts reversible dysfunction and quantitates the extent of irreversibly damaged myocardium after reperfusion of anterior myocardial infarction. J Am Coll Cardiol 1994:624-30.
231. Salustri A, Elhendy A, Caryfallydis P, et al. Prediction of improvement of ventricular function after first acute myocardial infarction using low-dose dobutamine stress echocardiography. Am J Cardiol 1994;74:853-6.
232. Cigarroa C, DeFilippi C, Brickner E, Alvarez L, Wait M, Grayburn P. Dobutamine stress echocardiography identifies hibernating myocardium and predicts recovery of left ventricular function after coronary revascularization. Circulation 1993:88:430-6.
233. La Canna G. Alfiere O, Giubbini R, Gargano M, Ferrari R, Visioli O. Echocardiography during infusion of dobutamine for identification of reversible dysfunction in patients with chronic coronary artery disease. J Am Coll Cardiol 1994:23:617-26.
234. Charney R, Swinger M, Cohen M, et al. Dobutamine echocardiography predicts recovery of hibernating myocardium following coronary revascularization [Abstract]. J Am Coll Cardiol 1992;19:176A.
235. Sehgal R, Lambert K, Saham G, Bonow R, Chaudhry K Prediction of viable myocardium by dobutamine echocardiography in patients with chronic left ventricular dysfunction. Clin Res 1993:41:641 A.
236. Arnese M, Cornel J, Salustri A, et al. Prediction of improvement of regional left ventricular function after surgical revascularization: a comparison of low-dose dobutamine echocardiography with thallium-201 single-photon emission computed tomography. Circulation 1995:91:2748-52.
237. Panza J, Dilsizian V, Laurienzo J, Curielm R. Katsiyiannis P. Relation between thallium uptake and contractile response to dobutamine: implications regarding myocardial viability in patients with chronic coronary artery disease and left ventricular dysfunction. Circulation 1995:91:990-8.
238. Baer F, Voth E. Deutsch H. et al. Assessment of viable myocardium by dobutamine Iransesophageal echocardiography and comparison with fluorine-18 flnorodeoxyglucose positron emission tomography. J Am Coll Cardiol 1994:24:343-53.
239. Hepner A, Bach D, Boiling S, et al. A positive dobutamine stress echocardiogram predicts viable myocardium in ischemic cardiomyopathy: a comparison with PET [Abstract]. Circulation 1994:90:1-117.
240. Elsner G. Sawada S, Foltz J, et al. Dobutamine stimulation detects stunned but not hibernating myocardium [Abstract]. Circulation 1994:90:1-117.
241. Afridi I. Kleiman N, Raizner A, Zoghbi W. Dobutamine echocardiography in myocardial hibernation-optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation 1995;91:663-70.
242. Chen C, Li L, Chen L, et al. Incremental doses of dobutamine induce a biphasic response in dysfunctional left ventricular regions subtending coronary stenoses. Circulation 1995;92:756-66.
243. Tauke J, Alessandrini R, et al. Prognostic value of dobutamine stress echocardiography in patients with left ventricular dysfunction. J Am Coll Cardiol 1995:23:62 A.
244. Sabia P, Powers E, Ragosta M, Sarebock I, Burwell L, Kaul S. An association between collateral blood flow and myocardial viability with recent myocardial infarction. N Engl J Med 1992:327:1825-31.
245. Milunksi M, Mohr G, Ferez J, et al. Ultrasonic tissue characterization with integrated backscatter: acute myocardial ischemia, reperfusion and stunned myocardium in patients. Circulation 1989:80:491-503.
246. Milunksi M, Mohr G, Wear K, Sobel B, Miller J, Wickline S. Early identification with ultrasonic integrated backscatter of viable but stunned myocardium in dogs. J Am Coll Cardiol 1989:14:462-71.
247. Valentini V, Pappas E, Parker M, Bonow R, Chaudhry E Does nitroglycerine enhance the identification of viable myocardium by dobutamine echocardiography? J Invest Med 1995;43:390A.
248. Brunken R, Kottou S, Nienaber C, et al. PET detection of viable tissue in myocardial segments with persistent defects at Tl-201 SPECT. Radiology 1989:65:65-73.
249. Tamaki N, Yonekura Y, Yamashita K, et al. SPECT thallium-201 tomography and positron tomography using N-13 ammonia and F-18 fluorodeoxyglucose in coronary artery disease. Am J Cardiac Imaging 1989;3:3-9.
250. Garcia E. Quantitative myocardial perfusion single-photon emission computed tomographic imaging: quo vadis? (Where do we go from here?). J Nucl Cardiol 1994;1:83-93.
251. Charney R, Schwinger M, Chung J, Cohen MV, et al. Dobutamine echocardiography and resting-redistribution thallium-201 scintigraphy predicts recovery of hibernating myocardium after coronary revascularization. Am Heart J 1994:128:864-9.
252. Simek C, Watson D, Smith W, Vinson E, Kaul S. Dipyridamole thallium-201 imaging versus dobutamine echocardiography for the evaluation of coronary artery disease in patients unable to exercise. Am J Cardiol 1993;72:1257-62.
253. Hendel R, Chaudhry F, Parker M, Klocke F Seghal R, Bonow R. Regional discordance in myocardial viability assessment with thallium-201 restredistribution imaging and low-dose dobutamine echocardiography [Abstract]. Circulation 1995:92:1-550.
254. Senior R, Raval U, Lahari A. Technetium-99m-labeled sestamibi imaging reliably identifies retained contractile reserve in dyssynergic myocardial segments. J Nucl Cardiol 1995:2:296-302.
255. Perrone-Filardi R Pace L, Squame F, et al. Do rest-redistribution thallium tomography and low-dose dobutamine echocardiography wield comparable viability information in dysfunction myocardium? [Abstract]. Circulation 1994:90:1-314.
256. Pirelli S, Crivellaro W, Faletra F, et al. Dobutamine stress echocardiography and rest thallium-201 scintigraphy in patients with previous myocardial infarction and single vessel coronary artery lesion: prediction of functional recovery after revascularization [Abstract]. J Am Coll Cardiol 1995:(special issue):340A.
257. Smart S, Knickolbine T, Carlos M, Hellman R, Wynsen J, Sagar K. Dobutamine echooardiography and rest SPECT Tl-201 scintigraphy are more concordant in detecting viability in hibernating than stunned myocardium [Abstract], J Am Coll Cardiol 1995;(special issun):126A.
258. Bonow R. The hibernating myocardium: implications for management of congestive heart failure. Am J Cardiol 1995:75:17A-25A.
259. Maddahi J, Schelbert H. Brunken R. et al. Rolo of thallium-201 and PET imaging in évaluation of myocardial viability and management of patients with coronary artery disoa.se and left ventricular dysfunction. I Nucl Med 1994;35:707-15.
260. Hendel R. Single-photon perfusion imaging for the assessment of myocardial viability. J Nucl Med 1994:35:238-31S.